Pomalidomide-PEG4-Ph-NH2

Background Introduction

Pomalidomide-PEG4-Ph-NH2 is a specialized E3 ligase ligand-linker conjugate commonly used in the design and synthesis of PROTACs (Proteolysis Targeting Chimeras). This bifunctional molecule features pomalidomide—a derivative of thalidomide known to recruit the cereblon (CRBN) E3 ubiquitin ligase—attached via a PEG4 (polyethylene glycol tetramer) linker to a terminal amine-functionalized phenyl ring. Its structure allows for modular attachment to small-molecule warheads, enabling targeted protein degradation. As interest in targeted protein degradation continues to rise, Pomalidomide-PEG4-Ph-NH2 plays a pivotal role in expanding the possibilities of novel drug discovery.

Mechanism

Pomalidomide-PEG4-Ph-NH2 operates by leveraging the PROTAC technology platform. The pomalidomide moiety acts as a CRBN E3 ligase ligand, specifically binding to the CRBN complex. The PEG4 spacer provides optimal flexibility and solubility, minimizing steric hindrance while maintaining appropriate distance between the two binding domains. The terminal aminophenyl group acts as a handle for conjugation to a variety of ligands that target a protein of interest (POI). Once a PROTAC is synthesized using this intermediate, it can simultaneously bind the target protein and CRBN, bringing them into proximity and facilitating ubiquitination and subsequent proteasomal degradation of the POI.

Applications

Pomalidomide-PEG4-Ph-NH2 is primarily utilized as a building block in the synthesis of PROTAC molecules for protein degradation studies. Its applications span target validation, drug discovery, and the development of new chemical probes for undruggable proteins. Researchers use this conjugate to design PROTACs aimed at degrading disease-associated proteins in oncology, immunology, and neuroscience. Additionally, the PEG4 linker enhances aqueous solubility and pharmacokinetic properties, making it suitable for both in vitro cellular assays and in vivo preclinical studies. The amine terminus allows for customizable conjugation via amide or urea bond formation with diverse targeting ligands, facilitating rapid SAR (structure-activity relationship) studies.

Pomalidomide-PEG4-Ph-NH2 is a versatile E3 Ligase Ligand-Linker Conjugate enhancing the efficacy of PROTACs by facilitating targeted protein degradation. It offers a unique combination of a pomalidomide-based ligand and a PEG linker, making it ideal for diverse research applications. The following provides a detailed description of this molecule.

Linker: The linker in Pomalidomide-PEG4-Ph-NH2 is a PEG4 chain, known for its flexible yet stable nature, spanning approximately 18 atoms. Its hydrophilic properties enhance solubility and bioavailability, while its non-cleavable design ensures stability during cellular processes.

Ligand: The ligand in this molecule is derived from pomalidomide, a well-characterized thalidomide analog. It features a glutarimide moiety that effectively recruits the CRBN E3 ligase, making it a potent agent for targeted protein degradation.

Reactive Site: The reactive site of Pomalidomide-PEG4-Ph-NH2 is the terminal amine group (Ph-NH2), which can couple with target protein ligands via amide bond formation. This site is suitable for reactions such as amidation or reductive amination, providing robust conjugation options.

Recommended Target Protein Ligand: An ideal warhead for this conjugate is a covalent inhibitor with an electrophilic group, such as an acrylamide moiety. These warheads enable the irreversible modification of cysteine residues on target proteins, facilitating efficient degradation. This approach is advantageous for studying protein function and validating therapeutic targets in preclinical research.